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Abstract
Background: For the better part of 100 years, acetaminophen (or paracetamol as it is known outside of the United
States) has been a common first-line analgesic in pediatrics and is typically well tolerated with minimal side
effects. Its use as an anti-pyretic is also well-documented and thus it is used broadly for symptom control in the
general pediatric population.
Discussion: In pediatric palliative care, acetaminophen is also used as an adjuvant to opioid therapy for pain as
well as an anti-pyretic. For many pediatric patients near end-of-life, however, the ability to tolerate oral intake is
diminished and rectal suppository administration can be distressing or contraindicated as in the setting of
neutropenia, thus limiting use of acetaminophen by its usual routes. In Europe and Australia, an intravenous
formulation of acetaminophen has been used for many years and has only recently become available in the
United States.
Conclusion: Here, we describe a case using intravenous acetaminophen in a pediatric patient at the end of life.
Introduction
For the better part of 100 years, acetaminophen (orparacetamol as it is known outside of the United States)
has been a common first-line analgesic in pediatrics and is
typically well tolerated with minimal side effects. Its use as an
antipyretic is also well documented and thus it is used
broadly in the general pediatric population. In pediatric
palliative care, acetaminophen is also used as an adjuvant to
opioid therapy for pain as well as an antipyretic. For many
pediatric patients near end-of-life, however, the ability to
tolerate oral intake is diminished. Likewise, rectal suppository
administration can be distressing or contraindicated as in the
setting of neutropenia, thus limiting use of acetaminophen by
its usual routes. In Europe and Australia, an intravenous
formulation of acetaminophen has been used for many years
and has only recently become available in the United States.
Here, we describe a case using intravenous acetaminophen in
a pediatric patient at the end of life.
Case Description
M.A. is an 8-year-old girl with a history of metastatic
Sertoli-Leydig cell tumor of the right ovary. She was first
diagnosed at age 6 and underwent surgical resection of the
mass. Despite no evidence of metastatic disease at the time of
diagnosis, the aggressive pathologic nature of the tumor led
M.A. to undergo systemic chemotherapy, which she com-
pleted without significant toxicity. A little over a year later,
M.A. presented with abdominal pain and was found to have a
large abdominal mass that upon surgical resection was di-
agnosed as recurrent disease. At this time, she was noted to
have metastatic lesions in multiple abdominal structures in-
cluding the omentum, cecum, uterus, and mesentery. She
again underwent systemic chemotherapy, which she toler-
ated well, but several months later developed an intermittent
malignant small bowel obstruction with episodic nausea,
vomiting, anorexia, and weight loss. M.A. underwent pallia-
tive radiation therapy in hopes of shrinking the mass and
relieving her obstructive symptoms. Because of her inability
to tolerate oral intake, MA was started on total parenteral
nutrition (TPN) to maintain nutrition. She required frequent
hospitalization for management of pain and other symptoms,
including recurrent fevers. Eventually, M.A. was started on
patient-controlled anlalgesia (PCA) for pain control, and her
parents opted to enroll M.A. in hospice.
For her fevers, M.A. underwent evaluation with blood and
urine cultures as well as abdominal imaging for possible ab-
scess. When these studies were negative and her fever curve
failed to respond to antibiotics, it was felt that they were most
likely related to her metastatic disease. The fevers themselves
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caused M.A. significant discomfort manifested by increased
irritability, diaphoresis, and tachycardia. Initially, M.A. was
put on as-needed rectal acetaminophen, which she did not
tolerate due to the discomfort and distress associated with the
mode of delivery. After much discussion with her parents, a
trial of intravenous acetaminophen at 15 mg/kg per dose
scheduled every 6 hours was initiated. Twenty-four hours
after initiation of intravenous acetaminophen therapy, M.A.
experienced an improvement in her fever curve and subjective
improvement in her fever-related symptoms. A few days la-
ter, she developed increasing bilirubin and imaging revealed
the interval development of biliary obstruction from the
tumor mass. Due to the risk of liver toxicity, scheduled in-
travenous acetaminophen was discontinued and M.A. was
started on intravenous dexamethasone prior to receiving
additional palliative chemotherapy. Eventually, M.A. was
discharged home with hospice services. On follow-up with
oncology, M.A. was fever-free on daily dexamethasone. She
died a little less than 1 month later.
Discussion
Fevers related to malignancy are common in patients with
metastatic disease and can be a cause of discomfort for patients
and distress for parents. Acetaminophen remains the main-
stay of antipyretic therapy, although the lack of an intrave-
nous formulation has limited its use in end-of-life care.
Propacetamol, an intravenous water soluble pro-drug of
acetaminophen, has been widely used in Europe for over 20
years but is not available in the United States.1 Although well
tolerated with a low side effect profile, the use of propaceta-
mol has been associated with rare cases of contact dermatitis
and pain at the site of injection.2,3 Developing alternatives has
been challenging due to acetaminophen’s poor solubility in
water. Recently, however, the development of an intravenous
formulation of acetaminophen has been approved by the FDA
in children older than 2 years of age and is associated with a
decreased risk of local reaction compared to propacetamol.3
The majority of data on the use of intravenous acetamino-
phen involve postoperative analgesia,4–6 although in the past
several years increasing evidence has accumulated regarding
the safety and efficacy of intravenous acetaminophen in pe-
diatric populations, including neonates.7–9
The standard dosing of intravenous acetaminophen in
pediatric patients is the same as for oral acetaminophen
(15 mg/kg every 4–6 hours with a maximum of 60 mg/kg per
day or 4 g/d) with each dose being run over 15 minutes.
Noninferiority trials in pediatric patients have shown that in
terms of analgesic and antipyretic effects, intravenous acet-
aminophen is no less effective than a comparable dose of in-
travenous propacetamol.10 In a number of countries including
Australia and most of Europe, intravenous acetaminophen
has been available for more than 5 years, and has recently
been approved for use in the United States. The side effects
and toxicity of intravenous acetaminophen compared to oral
acetaminophen appear to be similar, despite higher plasma
levels seen with intravenous acetaminophen.10 In our case, the
patient developed worsening liver function after initiation of
intravenous acetaminophen, though this was likely related to
her metastatic disease. Caution should be used in patients
with liver disease, chronic malnutrition, or severe renal im-
pairment.11 In addition, careful attention should be paid in
dosing intravenous acetaminophen as several cases of iatro-
genic dosing errors have been reported related to calculating
the dose based on milliliters rather than milligrams; given that
the solution comes in 10 mg/mL preparations, this results in a
tenfold overdose.12
In general, the oral route is the preferred method for
medication delivery in pediatric palliative care patients given
the relative discomfort associated with other preparations. In
this case, our patient had a preexisting central line for TPN,
and her parents, both medical professionals, had a great deal
of comfort with delivering intravenous medications. In other
situations, the difficulty of establishing and maintaining an
intravenous access and parental anxiety or uneasiness may
limit the utility of intravenous acetaminophen for pediatric
patients at the end of life. Furthermore, the cost of intravenous
acetaminophen (typically $5–$10 per 1000 mg) may limit
widespread use by hospice agencies.7
To the best of our knowledge, this is the first reported use
of intravenous acetaminophen in a pediatric patient at the end
of life. Our patient’s fever curve responded well to intrave-
nous acetaminophen and administration improved overall
comfort. This suggests a future role in select pediatric pa-
tients at the end of life who cannot tolerate other forms of
acetaminophen.
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